Cancer Survivorship, Exercise, and Mobility in Later Life

A cancer history in later life can be a warning flag for declining mobility, especially when walking speed, grip strength, or lower-body function has begun to slip. It is not proof that disability is inevitable. The best evidence here points to a practical response: structured exercise that combines walking, leg strengthening, balance work, and flexibility may help older cancer survivors preserve independence.

The strongest intervention result comes from a cancer-survivor subgroup within the LIFE randomized trial. It deserves attention because the outcome was not a questionnaire score or a wearable metric. It was the ability to walk 400 meters without help.

A mobility outcome that matters outside the gym

In Brown et al. 2025, researchers analyzed 371 cancer survivors enrolled in the LIFE trial, which originally randomized 1,635 sedentary adults aged 70 to 89 with functional limitation. Participants had a Short Physical Performance Battery score of 9 or lower at baseline.

The comparison was specific. One group received health education. The other began with two center-based exercise sessions each week and added three to four home sessions. Over two to three weeks, the program progressed toward 30 minutes of moderate-intensity walking a day, targeting 150 minutes per week. It also included roughly 10 minutes each of lower-extremity strengthening and balance training, plus flexibility work for major muscle groups.

Over a median 2.6 years in the parent trial, the physical-activity program reduced major mobility disability. The study defined that endpoint objectively: failure to complete a 400-meter walk within 15 minutes without sitting or another person's assistance. In the cancer-survivor subgroup, the physical-activity arm had about 43% lower risk of major mobility disability than the health-education arm.

That is the most useful result in this evidence base because it tests an intervention against a comparator and measures a real-world function tied to independence. Still, the 43% figure is a relative effect. The published information summarized here does not provide the subgroup's absolute risk reduction, number needed to treat, confidence interval, or detailed adverse-event counts. Those omissions matter. A large-looking relative reduction can translate into very different individual benefits depending on baseline risk.

Why cancer history may matter for walking

The intervention result has context. Luo et al. 2022 matched 452 women with incident breast cancer to 2,260 cancer-free controls and followed repeated objective measures of physical function for as long as 20 years. After diagnosis, breast-cancer survivors had faster declines in gait speed and grip strength than controls.

This was a longitudinal cohort study, not a trial, so it cannot establish that cancer itself caused the faster decline. Treatment exposure, illness burden, preexisting health, and other differences may contribute. But its repeated objective testing makes the result more informative than a one-time comparison of survivors with non-survivors.

The pattern also argues against a blunt story that cancer history steadily worsens every physical measure. Quadriceps strength dropped soon after diagnosis and then improved over time, while the abstract did not emphasize a clear chair-stand difference. Aging lowered function in both survivors and controls. The survivor-specific signal was clearest for gait speed and grip strength, which puts walking-related capacity at the center of the concern.

Different survivor groups may arrive at mobility problems by different routes. In survivors of acute lymphoblastic leukemia treated with chemotherapy alone, Fridh et al. linked neuropathy, sarcopenia, and poorer physical function. That makes neuropathy a plausible contributor for some people, not a universal explanation. Among childhood-cancer survivors, Schwartz et al. found that neighborhood characteristics were associated with frailty. Access, environment, and treatment history all shape the path from survivorship to function.

Why the program includes more than walking

The LIFE intervention was multicomponent for a reason. Walking builds walking tolerance, but leg strength and balance can determine whether someone can rise from a chair, recover from a stumble, or keep moving safely when terrain gets uneven.

Cancer-specific trials with the same hard mobility-disability endpoint remain limited, so the broader geriatric evidence provides indirect support. Shen et al. 2023 pooled 42 randomized trials involving 3,728 older adults with sarcopenia. Resistance-plus-balance training, with or without nutrition, improved usual gait speed by 0.16 m/s and handgrip strength by 4.19 kg. Resistance-based combinations improved chair-stand performance by about 1.72 to 2.28 seconds.

Those participants were older adults with sarcopenia, not cancer survivors, so the estimates should not be transplanted wholesale into oncology. They do support the idea that the capacities needed for independent movement remain trainable later in life. A second network meta-analysis, Zeng et al. 2023, likewise found that exercise improved strength and physical-performance measures in older adults with sarcopenia.

Other cancer studies show that structured training can be delivered in settings very different from the LIFE subgroup. Mikkelsen et al. 2022 tested a 12-week multimodal exercise program in older patients with advanced cancer. That supports feasibility in a population with greater disease burden, but it does not establish long-term prevention of mobility disability. A protocol that suits a stable survivor years after treatment may not suit someone with advanced disease, cachexia, or active toxicities.

Digital tools can help deliver a program; they have not replaced one

Wearables, apps, and gamified programs may make exercise easier to organize or stick with. In prostate-cancer patients receiving androgen-deprivation therapy, Park et al. 2021 tested an internet-of-things lifestyle intervention in a prospective multicenter randomized trial. This treatment setting is relevant because androgen deprivation can create metabolic and bone-related problems that complicate physical function.

Digital rehabilitation also improved access in a randomized postoperative liver-cancer study, Yu et al. 2025. Reviews of wearables and gamification in cancer populations report potential benefits for engagement and selected outcomes, including Ning et al. 2023. But these studies do not show that technology alone prevents long-term mobility disability in older survivors using the 400-meter endpoint from LIFE. A watch can remind you to train. It cannot perform your balance work for you.

Who should start cautiously

The LIFE model is a template, not a universal prescription. The cancer-survivor analysis pooled multiple cancer types, treatment histories, and likely times since diagnosis, and cancer history was self-reported. It was also a secondary subgroup analysis rather than a cancer-survivor-only trial designed and powered for that subgroup. These limits reduce certainty about the exact size of the benefit for any one survivor.

Individualization matters most when there is severe neuropathy, major balance impairment, advanced frailty, cardiopulmonary limitation, active treatment toxicity, or likely osteoporosis. These are reasons for clinical screening and an adapted start, not automatic reasons to avoid activity. A supervised start may be sensible for people who are sedentary, mobility-limited, or medically complex.

Exercise evidence also varies sharply by cancer phenotype. A 2021 Cochrane review of exercise for cancer cachexia covered a more severe and heterogeneous clinical syndrome than general late-life survivorship. Its findings should not be used to promise that one exercise plan will solve every oncology-related functional problem.

The practical verdict

For an older adult with a cancer history, a slowing gait or reduced walking tolerance deserves objective attention rather than dismissal as ordinary aging. The cohort evidence suggests that breast-cancer survivorship can coincide with faster decline in gait speed and grip strength. The randomized LIFE subgroup suggests that a structured program can lower major mobility-disability risk in sedentary, mobility-limited older survivors.

The evidence supports progressive walking paired with leg strengthening, balance training, and flexibility work—not vague advice to "be more active."

Build toward about 150 minutes a week of moderate-intensity walking if clinically appropriate, and include the other components that made the LIFE intervention multicomponent. Use digital tools if they improve adherence or access. Keep the main priority on the training, and get individualized guidance when treatment effects or medical conditions change the risk of falls, fractures, or exertional symptoms.